STOCK TITAN

Dynavax Technolo - DVAX STOCK NEWS

Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.

Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.

Core Products and Clinical Pipeline:

  • HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
  • CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
  • Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
  • Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
  • Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.

Recent Achievements and Financial Highlights:

  • Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
  • As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
  • For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.

Strategic Partnerships:

Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.

For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.

Rhea-AI Summary

Medigen Vaccine Biologics Corporation (MVC) and Dynavax Technologies Corporation (Nasdaq: DVAX) announced the rollout of MVC-COV1901, a COVID-19 vaccine, with an initial distribution to approximately 600,000 people in Taiwan. MVC recently received emergency use authorization from the Taiwan FDA for its two-dose vaccine, which utilizes Dynavax's CpG 1018 adjuvant. The vaccine showed promising safety and efficacy in clinical trials. MVC's CEO highlighted the importance of serving Taiwan during the pandemic, while Dynavax's CEO expressed hopes for further approvals of vaccines using their adjuvant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.37%
Tags
covid-19
-
Rhea-AI Summary

Dynavax Technologies (DVAX) reported Q2 2021 financial results showing significant growth. Total revenue reached $52.8 million, up from $2.7 million in Q2 2020. HEPLISAV-B net revenue was a record $13.7 million, while CpG 1018 contributed $39 million. The company announced a commercial supply agreement with Biological E for its COVID-19 vaccine candidate. Dynavax also increased its cash reserves to $345.8 million. The CDC is set to vote on a universal hepatitis B recommendation in October 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
-
Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX) announced on August 3, 2021, the granting of stock options to purchase 438,000 shares to 44 new employees. The options, granted on August 2, 2021, have an exercise price of $9.45 per share, aligning with the closing stock price on that date. Each option has a 7-year term and vests over three years, with one-third vesting after one year. This action complies with Nasdaq Listing Rule 5635(c)(4) aimed at incentivizing new hires.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
Rhea-AI Summary

Dynavax Technologies Corporation (NASDAQ: DVAX) is set to report its second quarter 2021 financial results on August 4, 2021, following the close of U.S. markets. A conference call will occur the same day at 4:30 p.m. ET. The company, known for its HEPLISAV-B® Hepatitis B vaccine, continues to develop novel vaccines and adjuvants, including collaborations for COVID-19 and other significant vaccines. The live webcast will be available on their investors’ website, with replay options for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences earnings
-
Rhea-AI Summary

Dynavax Technologies (DVAX) announced a commercial supply agreement with Biological E. Limited for its CpG 1018 adjuvant, aimed at enhancing BE's COVID-19 vaccine candidate, CORBEVAX™. The agreement extends through 2022, covering doses manufactured under prior funding from the Coalition for Epidemic Preparedness Innovations (CEPI). In June 2021, India's Ministry of Health secured 300 million doses of CORBEVAX™. Ryan Spencer, CEO of Dynavax, expressed pride in the collaboration, while BE's Managing Director emphasized the vaccine's potential in combating the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
covid-19
-
Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) has granted nonstatutory stock options for 51,000 shares to five new employees as an inducement for employment. The options, with an exercise price of $10.23 per share, were issued on July 1, 2021, and are set to vest over three years. Each option has a 7-year term and vests one-third after one year, with the remainder vesting monthly. This action complies with Nasdaq Listing Rule 5635(c)(4) and is part of the 2021 Inducement Award Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
none
Rhea-AI Summary

Clover Biopharmaceuticals and Dynavax Technologies have entered a commercial supply agreement for Dynavax's CpG 1018 adjuvant, intended for use in Clover's SCB-2019 COVID-19 vaccine. The agreement is valid through 2022 and includes doses manufactured under prior funding. Clover also announced an advanced purchase agreement with Gavi for up to 414 million doses of SCB-2019 via the COVAX Facility, pending regulatory approvals. The vaccine aims for a product launch by the end of 2021, following clinical trial data expected mid-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
covid-19
-
Rhea-AI Summary

Clover Biopharmaceuticals has entered into a commercial supply agreement with Dynavax Technologies for the CpG 1018 adjuvant to be used in the production of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum). The deal extends until the end of 2022, with doses to be delivered in 2021. Clover also announced an advanced purchase agreement with Gavi for up to 414 million doses through 2022. Pending regulatory approvals, SCB-2019 is expected to launch by the end of 2021 to supply the COVAX Facility and direct government procurement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
covid-19
-
Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) announced the appointment of John Slebir as Senior Vice President and General Counsel on June 28, 2021. To incentivize his employment, the company granted him a non-statutory stock option to purchase 300,000 shares at an exercise price of $9.29 per share, which matches the closing price on the grant date. The option has a 7-year term and vests over three years. This grant complies with Nasdaq Listing Rule 5635(c)(4) as part of Dynavax's 2021 Inducement Award Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) will have its CEO, Ryan Spencer, present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 3:50 p.m. E.T. The presentation will be accessible via webcast through the company's website's 'Events & Presentations' section.

Dynavax specializes in developing novel vaccines, with its first product HEPLISAV-B® approved in the U.S. and EU for hepatitis B prevention in adults. The company is also advancing research on vaccine adjuvants, including collaborations for COVID-19 vaccines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
conferences

FAQ

What is the current stock price of Dynavax Technolo (DVAX)?

The current stock price of Dynavax Technolo (DVAX) is $13.33 as of February 21, 2025.

What is the market cap of Dynavax Technolo (DVAX)?

The market cap of Dynavax Technolo (DVAX) is approximately 1.6B.

What is Dynavax Technologies Corporation known for?

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company specializing in developing vaccines for infectious and inflammatory diseases, and cancer.

What are the key products of Dynavax?

Dynavax's key products include the HEPLISAV-B® hepatitis B vaccine and the CpG 1018® adjuvant used in multiple COVID-19 vaccines.

What is HEPLISAV-B®?

HEPLISAV-B® is an adult hepatitis B vaccine approved in the U.S., EU, and Great Britain, known for enabling series completion with only two doses in one month.

What is the significance of the CpG 1018® adjuvant?

The CpG 1018® adjuvant enhances the immune response in vaccines, including those for COVID-19, shingles, Tdap, and plague.

Who are Dynavax's key partners?

Dynavax collaborates with global biopharmaceutical companies, including AstraZeneca in Europe.

What are the recent financial highlights of Dynavax?

In 2023, Dynavax achieved record revenue growth for HEPLISAV-B and reported substantial cash reserves of $742.3 million as of December 31, 2023.

What is the clinical pipeline focus of Dynavax?

Dynavax's clinical pipeline focuses on differentiated vaccine candidates leveraging the CpG 1018® adjuvant for shingles, Tdap, plague, seasonal influenza, and universal influenza.

How does Dynavax plan to sustain its growth?

Dynavax aims to sustain growth through strategic partnerships, advancing its clinical pipeline, and increasing market share for HEPLISAV-B.

How can investors get updates on Dynavax?

Investors can follow updates on Dynavax through the 'Events & Presentations' page on the company's official website.

What are the most common adverse reactions to HEPLISAV-B?

The most common adverse reactions include injection site pain, fatigue, and headache.
Dynavax Technolo

Nasdaq:DVAX

DVAX Rankings

DVAX Stock Data

1.63B
123.46M
0.34%
104.39%
14.58%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
EMERYVILLE